Ranbaxy’s Private-Label Loratadine OTCs Spared By FDA Probe
This article was originally published in The Tan Sheet
Executive Summary
Several first-to-file abbreviated new drug applications are on the line as Ranbaxy tries to resolve data integrity issues with FDA concerning its Paonta Sahib, India, facility